Imaging Recommendations for Diagnosis, Staging, and Management of Gastric Cancer

Argha Chatterjee1, Diva Shah2, Biprasad Roy3, Joydeep Ghosh4, Soumendranath Ray5, Anurima Patra1, Anisha Gehani1, Bharat Gupta1, Priya Ghosh1, Sumit Mukhopadhyay1, Aditi Chandra1, Dayananda Lingegowda1, Saugata Sen1

1 Department of Radiology and Imaging, Tata Medical Center, Kolkata, West Bengal, India
2 Consultant Radiologist, HCG Cancer Center, Ahmedabad, Gujarat, India
3 Department of GI and HPB Surgery, Department of Radiology and Imaging, Tata Medical Center, Kolkata, West Bengal, India
4 Department of Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India
5 Department of Nuclear Medicine, Tata Medical Center, Kolkata, West Bengal, India

Address for correspondence Argha Chatterjee, MD, Department of Radiology and Imaging, Tata Medical Center, Kolkata, West Bengal 700156, India (e-mail: arghachat84@gmail.com).

Abstract

Gastric cancer is the second most common cause of cancer-related death in Indian men and women aged between 15 and 44 years. Most patients present at an advanced stage of disease. Surgically resectable disease usually requires a standard gastric resection and D2 lymphadenectomy. Imaging, especially with computed tomography scan of abdomen as well as thorax, is necessary for localization, nodal mapping, and metastatic workup of gastric cancer. In this review, we discuss current imaging recommendations for gastric carcinoma.

Keywords
- computed tomography
- gastric carcinoma
- imaging
- imaging

Introduction

Gastric cancer is the second most common cause of cancer-related death in Indian men and women aged between 15 and 44 years.1 Most patients present at an advanced stage of disease. Surgically resectable disease usually requires a standard gastric resection and D2 lymphadenectomy. Imaging, especially with computed tomography (CT) scan of abdomen as well as thorax, is necessary for localization, nodal mapping, and metastatic workup of gastric cancer.

Risk Factors and Etiopathogenesis

Risk factors may differ for proximal and distal gastric cancers. The important risk factors include gastric adenomas or dysplasia, chronic atrophic gastritis, previous gastric surgery, Helicobacter pylori infection, high intake of pickled, smoked, salted, or preserved foods, smoking and alcohol consumption, obesity, and family history.2-4

Epidemiology and Clinical Presentation—India and Global

Gastric carcinoma is currently the fifth most common cancer worldwide and accounts for 8.2% of all cancer-related deaths globally.5 There is substantial geographic variation in gastric cancer incidence. High age-standardized incidence rate is seen in the high-income Asia Pacific region (Japan, South Korea), with incidences of 29.5 per thousand population, followed by Eastern Europe and Andean Latin America. In contrast, India has relatively low rates of gastric carcinoma, with an age-standardized incidence rate of 7.5 per 100,000 population.6 Gastric cancer is the second most common cause of cancer-related death in Indian men and women aged between 15 and 44 years.1 Highest incidence is reported from north-eastern and southern parts of India.7 Most patients present at an advanced stage of disease. Standard gastric resection and D2 lymphadenectomy offer the best chance of survival. The overall survival for gastric...
carcinoma is poor and the 5-year survival rate with surgical treatment alone ranges between 23 and 25%.8

Clinical features of gastric carcinoma include weight loss, persistent abdominal pain, dysphagia (proximal tumors), gastric outlet obstruction and/or vomiting (distal tumors), occult gastrointestinal bleeding with or without iron deficiency anemia, and signs or symptoms of distant metastases that include palpable nodes such as left supraclavicular node (Virchow’s node), periumbilical nodes (Sister Mary Joseph node), and left axillary node (Irish node). Patients may also present with ascites from peritoneal spread.

**Diagnostic Workup**

Other than history, physical examination, and cross-sectional imaging, the diagnostic workup of suspected gastric cancer includes:

- Complete blood count and comprehensive chemistry profile.
- Endoscopy and biopsy. In case of metastatic disease, human epidermal growth receptor 2 (HER-2), Programmed cell death protein 1 (PD-1) and Microsatellite instability (MSI) testing are recommended. Histology should be reported according to the World Health Organization criteria. A histopathology confirmation is mandatory before definitive treatment.
- Biopsy of metastatic disease, as clinically indicated.
- Staging laparoscopy: Staging laparoscopy can upstage up to 30% of tumors. It is indicated for stage IB to III gastric cancer (as assessed by clinicoradiological examination) to determine treatment intent before commencement of neoadjuvant therapy.9 It is desirable to collect peritoneal washings during laparoscopy.10

**Imaging Guidelines**

**Screening**

Some countries with high incidence of gastric carcinoma (such as Japan) have national screening programs. These programs are not evident on conventional CECT. Routine use of 18F-fluorodeoxyglucose (FDG) PET-CT offers no significant incremental value over and above CECT as up to one third of cases of gastric cancer are not FDG avid.7 In one retrospective study, only a small percentage of nodes were spotted in PET-CT that were not identified by conventional staging CT.14

Some studies support the use of PET in gastric cancer staging, particularly in characterizing distant metastases or lymphatic metastases beyond D1 or D2 compartment. In postoperative cases with suspected recurrence, equivocal findings on CECT can be better characterized with the added metabolic information of FDG-PET as disease recurrence may be difficult to identify in some cases due to altered anatomy.

**Technique of CECT**

CECT for gastric cancer is done in two phases: noncontrast and portal venous phase (Table 1). An additional arterial phase is optional and may be helpful in the evaluation of arterial anatomy and detection of very early lesions. Iodinated contrast media (iodine concentration 300/320/350) is usually given as intravenous (IV) contrast at a dose of 1.5 mL/kg body weight through the antecubital vein at a rate of 3 mL/s. Neutral or negative oral contrast is preferred for optimal distension of stomach and duodenum. Approximately 1,000 to 1,200 mL of plain water usually provide sufficient distension. Injection Buscopan is not recommended.

**Primary Tumor Staging**

The primary tumor, if identified in CT, is to be described according the following subheadings:

- **Site**
  - Gastric cardia, proximal stomach, distal stomach. For proximal tumors, the relation of the epicenter of the cardia according to the Siewert classification is to be mentioned (Fig. 1).
- **Extent**
  - Focal, segmental, or diffuse.
- **Size**
  - Three dimensions of focal lesions; maximum length of the involved segment in segmental lesion.
  - Relationship with adjacent structures: Involvement of surrounding structures especially gastrohepatic ligament, duodenum, pancreas, left adrenal, and colon.
Identify periarterial cuffing /thickening along celiac axis and its branches/identify small perigastric veins and extramural venous invasion; optional).¹⁵

**Nodal Status**
Lymphatic spread is found in 74 to 88% of gastric cancers at diagnosis.¹⁶ Presence of nodes in preoperative staging warrants perioperative chemotherapy and indicates higher chance of local recurrence. In staging CT, nodes larger than 6 to 8 mm in the short axis are considered significant.¹⁷

**Metastasis**
- Liver, omentum, peritoneum, lungs, bone, ovaries, and rectovesical pouch.
  - Presence of ascites and if present, its predominant location and nature (attenuation and internal septations).
  - Synchronous primary lesion elsewhere in the esophagus or stomach.

**Arterial Anatomy**
Celiac artery and its branches and any anatomic arterial variation thereof is desirable to be mentioned in the preoperative evaluation.

**Chemotherapy Response Assessment**
Assessment of response following perioperative chemotherapy is currently performed with multidetector computed tomography (MDCT) and/or FDG-PET/CT. On CT, the Response Evaluation Criteria in Solid Tumors (RECIST) criteria is considered the method of choice in the assessment of response; however, the primary gastric tumor has been considered unmeasurable according to RECIST. Response assessment focuses on short axis measurement of involved lymph nodes and exclusion of disease progression. CT tumor volumetry (TV) to accurately measure the primary tumor is shown to be useful. A 15% reduction in tumor volume was considered a partial response.

---

**Fig. 1** Siewert classification of gastroesophageal junction (GEJ) carcinoma. Type I, epicenter of the lesion 1 to 5 cm above the GEJ; type II, epicenter of the lesion within a point 1 cm above to a point 2 cm below the GEJ; and, type III, epicenter of the lesion is 2 to 5 cm below GEJ (arrow).

**Table 1** Imaging parameters of CT scan of abdomen in gastric carcinoma

<table>
<thead>
<tr>
<th>Purpose</th>
<th>Noncontrast</th>
<th>Arterial</th>
<th>Portal venous</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purpose</td>
<td>Baseline</td>
<td>Vascular anatomy for surgical planning. Delineation of early tumors</td>
<td>Extent of tumor, liver metastases, other metastases</td>
</tr>
<tr>
<td>Area covered</td>
<td>Xiphisternum to symphysis pubis</td>
<td>Xiphisternum to iliac crest</td>
<td>Xiphisternum to symphysis pubis</td>
</tr>
<tr>
<td>FOV (mm)</td>
<td>422–500</td>
<td>380</td>
<td>450</td>
</tr>
<tr>
<td>kV</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>mAs</td>
<td>Auto</td>
<td>Auto</td>
<td>Auto</td>
</tr>
<tr>
<td>Slice thickness (mm)</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Interslice gap (mm)</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Reconstruction thickness (mm)</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Reconstruction interval (mm)</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
</tr>
</tbody>
</table>

Abbreviations: CT, computed tomography; FOV, field of view.
volume evaluated with MDCT has been shown to correlate with histologic response.\textsuperscript{18} FDG-PET/CT is not routinely used for treatment response. More evidence is needed to use Positron Emission Tomography (PET) Response Criteria in Solid Tumors criteria in chemotherapy follow-up.\textsuperscript{19}

**Postoperative Imaging**

Most advanced gastric carcinoma requires neoadjuvant chemotherapy followed by proximal, distal, subtotal or total gastrectomy, depending upon site and location of malignancy. Other than response evaluation following surgery and subsequent chemotherapy, if any, imaging is necessary in cases in immediate or early postoperative period.

Gastrectomy with D2 lymph node clearance is associated with postoperative complications such as bleeding, anastomotic leak, sepsis, duodenal blow out, intestinal obstruction, and pulmonary complications. If the patient deviates from the normal recovery pathway in the postoperative period, then the patient may require imaging.

Often a noncontrast CT of abdomen and pelvis is sufficient. Oral contrast is given when obstruction or leak is suspected. IV contrast is given when bleeding is suspected.

Reporting checklist of a postoperative CT in gastric cancer includes:

- Pleural effusion or basal atelectasis.
- Any collection at perioperative site or anastomotic site.
- Status of bowel (small/large bowel) dilatation/narrowing.
- Area of stenosis or narrowing or abnormal wall thickening in anastomotic site or bowel and to look for normal passage of oral contrast.
- Look for a stoma site, if any.
- Look for intra-abdominal drains and their position.
- Ascites.

**Principles of Management**

**Surgery**

**Resectable Lesions**

The standard oncological resection for gastric cancer involves resection of at least two-thirds of the stomach along with D2 lymph node clearance. The type of resection depends on the location of the tumor, which includes total gastrectomy (includes cardia and pylorus), distal gastrectomy (two-thirds of distal stomach), and proximal gastrectomy (including gastro-esophageal junction).\textsuperscript{20} A proximal resection margin of at least 3 cm is recommended for mass-forming and ulcerative lesions and of at least 5 cm of the same for infiltrative lesions. En bloc resection of the gastric cancer along with resection of left lateral section of liver, spleen, tail of pancreas, diaphragm can be done to achieve R0 resection. However, in cases of involvement of the second portion of duodenum, an extended resection of the head or body of the pancreas or the hepato-duodenal ligament is not recommended.

Nodal resection: D1: perigastric nodes; D2: nodes along left gastric artery (LGA), common hepatic artery (CHA), splenic artery, and celiac axis.

Splenectomy is indicated when there is direct splenic involvement from a greater curvature tumor.

For selected cases of peritoneal carcinomatosis (low volume peritoneal metastases or isolated cytology positive), a multimodal and aggressive treatment, including neoadjuvant chemotherapy (systemic, intraperitoneal, or a combination of these), curative gastrectomy, D2 lymphadenectomy along hyperthermic intraperitoneal chemotherapy can be beneficial.\textsuperscript{21}

**Palliative Surgery**

Palliative surgery is only indicated for relieving symptoms like bleeding or obstruction in presence of metastases. There is no advantage of cytoreductive surgery over palliative chemotherapy in the presence of metastatic disease.\textsuperscript{22} Gastrojejunostomy is preferred over stenting in cases of obstruction, if surgery can be done, and prognosis is reasonable. Nodal resection not indicated.

**Interventional Radiology**

Role of interventional radiology is limited to embolization for bleeding that is not controlled by endoscopic methods or relieving of obstruction by placement of a stent or gastrostomy tube.

**Chemotherapy and Immunotherapy**

In case of localized or locally advanced disease, the treatment intent becomes curative. The current standard of care is FLOT regime (fluorouracil, leucovorin, oxaliplatin, and docetaxel), which comprises four cycles of neoadjuvant FLOT chemotherapy followed by surgery and another four cycles of FLOT. FLOT has shown to increase overall survival compared with the ECF/ECX (epirubicin-cisplatin-capecitabine), the previous standard of care (hazard ratio: 0.77; 95% confidence interval: 0.63–0.94).\textsuperscript{23} In case of metastatic cancer, the treatment depends on the combined positive score. If it is high, there is a role of immunotherapies like pembrolizumab/nivolumab in combination with a standard CAPOX/FOLFOX-based regimen to improve overall survival. Treatment depends on PD-L1 combined positive score. In case of low immune score, the standard of care remains chemotherapy alone.\textsuperscript{24,25} In the case of HER 2 positive tumors, adding trastuzumab with standard chemotherapy regimens has shown to improve survival.\textsuperscript{26,27}

**Follow-Up Imaging**

For early disease (pT1, pT1) treated by endoscopic resection, CT TAP is indicated only when there is clinical concern for recurrence. In cases of pathological (Yp) stage I to III cases, CT TAP every 6 to 12 months is indicated for 2 years, then annually for up to 5 years.

**Summary of Recommendations**

- Diagnosis of gastric carcinoma is done by endoscopy and biopsy.
- For primary staging of early lesions, endoscopic ultrasound and/or endoscopic resection is necessary.
For primary staging of other lesions, CT TAP is recommended. PET has a limited role.
For T3 and above lesions, diagnostic laparoscopy with peritoneal washing is recommended.
In follow-up after chemotherapy and postoperative cases, the imaging method of choice is CT.

References
7 ICMR Subcommittee on Gastric Cancer ICMR: Consensus Document for Management of Gastric Cancer. Indian Council of Medical Research, editor. ICMR Subcommittee on Gastric Cancer. Indian Council of Medical Research; 2014;1–75
15 Yang YT, Dong SY, Zhao J, Wang WT, Zeng MS, Rao SX. CT-detected extramural venous invasion is correlated with presence of lymph node metastasis and progression-free survival in gastric cancer. Br J Radiol 2020;93(1116):20200673